CN101678008A - 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性 - Google Patents

坦罗莫司对乳头状肾细胞癌的抗肿瘤活性 Download PDF

Info

Publication number
CN101678008A
CN101678008A CN200880011269A CN200880011269A CN101678008A CN 101678008 A CN101678008 A CN 101678008A CN 200880011269 A CN200880011269 A CN 200880011269A CN 200880011269 A CN200880011269 A CN 200880011269A CN 101678008 A CN101678008 A CN 101678008A
Authority
CN
China
Prior art keywords
cell carcinoma
renal cell
cci
papillary renal
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011269A
Other languages
English (en)
Chinese (zh)
Inventor
G·杜卡特
J·J·小吉邦斯
A·贝尔肯布利特
J·M·范戈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39619123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101678008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101678008A publication Critical patent/CN101678008A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN200880011269A 2007-04-10 2008-04-08 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性 Pending CN101678008A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92275907P 2007-04-10 2007-04-10
US60/922,759 2007-04-10
PCT/US2008/004501 WO2008124125A1 (en) 2007-04-10 2008-04-08 Anti-tumor activity of temsirolimus in papillary renal cell cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610140376.1A Division CN105769861A (zh) 2007-04-10 2008-04-08 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性

Publications (1)

Publication Number Publication Date
CN101678008A true CN101678008A (zh) 2010-03-24

Family

ID=39619123

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880011269A Pending CN101678008A (zh) 2007-04-10 2008-04-08 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性
CN201610140376.1A Pending CN105769861A (zh) 2007-04-10 2008-04-08 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610140376.1A Pending CN105769861A (zh) 2007-04-10 2008-04-08 坦罗莫司对乳头状肾细胞癌的抗肿瘤活性

Country Status (23)

Country Link
US (1) US8791097B2 (enExample)
EP (5) EP2462934B1 (enExample)
JP (2) JP5908669B2 (enExample)
KR (2) KR101544222B1 (enExample)
CN (2) CN101678008A (enExample)
AU (1) AU2008236621B2 (enExample)
CA (1) CA2681451C (enExample)
CL (1) CL2008001009A1 (enExample)
CY (2) CY1116492T1 (enExample)
DK (2) DK2462934T3 (enExample)
ES (2) ES2586739T3 (enExample)
HR (2) HRP20150678T1 (enExample)
HU (2) HUE026022T4 (enExample)
IL (1) IL200835A (enExample)
MX (1) MX2009010954A (enExample)
PA (1) PA8776101A1 (enExample)
PL (2) PL2144611T3 (enExample)
PT (2) PT2144611E (enExample)
RU (1) RU2501559C2 (enExample)
SI (2) SI2462934T1 (enExample)
TW (1) TW200901989A (enExample)
WO (1) WO2008124125A1 (enExample)
ZA (1) ZA200907063B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2550964A1 (en) * 2011-07-26 2013-01-30 Universitat Pompeu-Fabra Temsirolimus for use in the prevention and/or treatment of a delta 9-tetrahydrocannabinol-induced anxiety disorder
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN108143732A (zh) * 2017-12-19 2018-06-12 江南大学 雷帕霉素和ω-3脂肪酸在制备治疗肾癌的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ATE296638T1 (de) * 1999-04-08 2005-06-15 Schering Corp Behandlung von nierenzellen-karzinom
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
JP2006506353A (ja) 2002-09-17 2006-02-23 ワイス 経口処方
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
MXPA05010582A (es) 2003-04-22 2005-11-23 Wyeth Corp Combinaciones antineoplasicas.
UA83245C2 (en) 2003-08-07 2008-06-25 Уайт Regioselective synthesis of cci-779
AR047988A1 (es) 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL E. BURCZYNSKI ET AL.: "Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma", 《CLINICAL CANCER RESEARCH》 *

Also Published As

Publication number Publication date
BRPI0809322A2 (pt) 2014-09-23
RU2009134479A (ru) 2011-05-20
SI2462934T1 (sl) 2016-07-29
PL2462934T3 (pl) 2016-10-31
JP5908669B2 (ja) 2016-04-26
WO2008124125A1 (en) 2008-10-16
CN105769861A (zh) 2016-07-20
JP2015083595A (ja) 2015-04-30
US8791097B2 (en) 2014-07-29
RU2501559C2 (ru) 2013-12-20
IL200835A0 (en) 2010-05-17
EP2144611B1 (en) 2015-06-17
US20080255177A1 (en) 2008-10-16
KR20090130040A (ko) 2009-12-17
EP2144611A1 (en) 2010-01-20
HUE029052T2 (hu) 2017-01-30
HUE026022T4 (hu) 2017-09-28
KR101544222B1 (ko) 2015-08-12
ZA200907063B (en) 2011-03-30
EP3106164A1 (en) 2016-12-21
HRP20150678T1 (hr) 2015-08-14
ES2586739T3 (es) 2016-10-18
PL2144611T3 (pl) 2015-10-30
EP2462934A1 (en) 2012-06-13
HRP20160698T1 (hr) 2016-07-15
DK2462934T3 (en) 2016-08-15
IL200835A (en) 2015-09-24
MX2009010954A (es) 2009-10-29
AU2008236621A1 (en) 2008-10-16
TW200901989A (en) 2009-01-16
PT2462934T (pt) 2016-08-17
KR20150002887A (ko) 2015-01-07
PA8776101A1 (es) 2009-03-31
CA2681451C (en) 2016-08-02
CA2681451A1 (en) 2008-10-16
EP3248601A1 (en) 2017-11-29
CY1117701T1 (el) 2017-05-17
ES2543853T3 (es) 2015-08-24
HUE026022T2 (hu) 2016-05-30
CL2008001009A1 (es) 2008-10-17
JP2010523660A (ja) 2010-07-15
PT2144611E (pt) 2015-09-11
EP3398597A1 (en) 2018-11-07
SI2144611T1 (sl) 2015-08-31
CY1116492T1 (el) 2017-03-15
EP2144611B9 (en) 2016-05-18
DK2144611T3 (en) 2015-08-10
AU2008236621B2 (en) 2013-06-27
EP2462934B1 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
CA2736361C (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US20050272758A1 (en) Antineoplastic combinations of CCI-779 and rituximab
AU2007201324A1 (en) Use of CCI-779 as an antineoplastic agent
TW201713327A (zh) 治療癌症之方法
AU2008236621B2 (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
TW201713328A (zh) 治療癌症之方法
TW201709905A (zh) 治療癌症之方法
JP2025508548A (ja) 淡明細胞型腎細胞癌の治療
CN1901906B (zh) 治疗套细胞淋巴瘤的cci-779
HK1226654A (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
HK1226654A1 (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
HK1142538A (en) Anti-tumor activity of temsirolimus in papillary renal cell cancer
KR20080034151A (ko) 암 치료를 위한 조스퀴다르, 다우노루비신 및 시타라빈
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
BRPI0809322B1 (pt) Uso de um composto
HK1158056A (en) Use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid as an antineoplastic agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142538

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100324

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142538

Country of ref document: HK